期刊
INNATE INFLAMMATION AND STROKE
卷 1207, 期 -, 页码 143-148出版社
BLACKWELL PUBLISHING
DOI: 10.1111/j.1749-6632.2010.05761.x
关键词
PMN leukocytes; ischemic stroke; inflammation; clinical studies; treatment
资金
- NIH [NS 026945, NS 053716, NS 038710]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS053716, R37NS038710, R01NS038710, R01NS026945] Funding Source: NIH RePORTER
In preparation for designing and undertaking trials of strategies that can modulate innate inflammation to improve outcomes of ischemic injury, consideration of approaches that have managed cellular inflammation in ischemic stroke are instructive. Robust experimental work has demonstrated the efficacy (and apparent safety) of targeting PMN leukocyte-endothelial cell interactions in the early moments following focal ischemia onset in model systems. Four clinical trial programs were undertaken to assess the safety and efficacy of inhibitors to PMN leukocyte interactions with the endothelial cell during ischemic stroke. Experiences in those clinical trial programs indicate specific limitations that halted progress in this line of investigation before an adequate hypothesis test could be achieved. Although innate inflammation is a central part of injury evolution following focal ischemia, great care in the translation from experimental studies to Phase I/II clinical safety assessments and to the design and conduct of Phase III trials is needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据